Individualization of piperacillin dosing for critically ill patients: Dosing software to optimize antimicrobial therapy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4094-4102

  Felton, T W ^a   Roberts, J A ^b   Lodise, T P ^c   Van Guilder, M ^d   Boselli, E ^e   Neely, M N ^d   Hope, W W ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PIPERACILLIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BAYESIAN LEARNING; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HOSPITAL INFECTION; HUMAN; INDIVIDUALIZATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICHAELIS MENTEN KINETICS; OPTIMAL DRUG DOSE; POPULATION MODEL; PRIORITY JOURNAL; STATISTICAL MODEL; VERY ELDERLY; ADOLESCENT; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BAYES THEOREM; BLOOD; COMPUTER ASSISTED DRUG THERAPY; CRITICAL ILLNESS; DOSE CALCULATION; DRUG EFFECTS; METABOLIC CLEARANCE RATE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; PSEUDOMONAS AERUGINOSA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BAYES THEOREM; CREATININE; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PRECISION MEDICINE; PSEUDOMONAS AERUGINOSA; YOUNG ADULT;

EID: 84903147784     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02664-14     Document Type: Article

References (38)

1. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall J-R, Payen D. 2006. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34:344-353. http://dx.doi.org/10.1097/01.CCM.0000194725.48928.3A. (Pubitemid 43145611)
2. Martin GS, Mannino DM, Eaton S, Moss M. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348:1546-1554. http://dx.doi.org/10.1056/NEJMoa022139. (Pubitemid 36437931)
3. Kollef MH. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474. http://dx.doi.org/10.1378/chest.115.2.462. (Pubitemid 29083057)
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9. (Pubitemid 43810035)
5. Roberts JA, Lipman J. 2006. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet. 45:755-773. http://dx.doi.org/10.2165/00003088-200645080-00001.
6. Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP. 2012. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob. Agents Chemother. 56:4087-4094. http://dx.doi.org/10.1128/AAC.00521- 12.
7. Patel N, Scheetz MH, Drusano GL, Lodise TP. 2010. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob. Agents Chemother. 54:460-465. http://dx.doi.org/10.1128/AAC.00296-09.
8. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10.1038/ nrmicro862. (Pubitemid 39490099)
9. Rello J, Ulldemolins M, Lisboa T, Koulenti D, Mañez R, Martin-Loeches I, De Waele JJ, Putensen C, Guven M, Deja M, Diaz E, EU-VAP/CAP Study Group. 2011. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur. Respir. J. 37:1332-1339. http://dx.doi.org/10.1183/09031936.00093010.
10. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10. http://dx.doi.org/10.1086/516284.
11. Lodise TP, Lomaestro BM, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44:357-363. http://dx.doi.org/10.1086/ 510590. (Pubitemid 46147617)
12. Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. 2013. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin. Infect. Dis. 56:236-244. http://dx.doi.org/10.1093/cid/cis856.
13. Tam VH, Schilling A, Neshat S. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 4920-4927. http://dx.doi.org/10. 1128/AAC.49.12.4920-4927.2005. (Pubitemid 41778901)
14. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57:5811-5819. http://dx.doi.org/10.1128/AAC.00867-13.
15. Hayashi Y, Roberts JA, Paterson DL, Lipman J. 2010. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin. Drug Metab. Toxicol. 6:1017-1031. http://dx.doi.org/10.1517/17425255.2010.506187.
16. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. http://dx.doi.org/10.1086/524669. (Pubitemid 351269158)
17. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA. 1999. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther. Drug Monit. 21:63-73. http://dx.doi.org/10.1097/00007691-199902000-00010. (Pubitemid 29077456)
18. International Association of Therapeutic Drug Monitoring and Clinical Toxicology. 2011. Definition of TDM. International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Kingston, Ontario, Canada. http://www.iatdmct.org/about-us/about-association/about-definitions-tdm-ct.html.
19. Roberts JA, Ulldemolins M, Roberts MS, McWhinney BC, Ungerer J, Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of betalactams in critically ill patients: proof of concept. Int. J. Antimicrob. Agents 36:332-339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.
20. Lodise TP, Lomaestro BM, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724. http://dx.doi.org/10. 1128/AAC.48.12.4718-4724.2004. (Pubitemid 39577677)
21. Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux M-C, Bouvet L, Chassard D, Allaouchiche B. 2008. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit. Care Med. 36:1500-1506. http://dx.doi.org/10.1097/CCM.0b013e318170ba21. (Pubitemid 351620671)
22. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
23. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit. 34:467-476. http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6.
24. Jelliffe RW, Bayard D, Schumitzky A, Milman M, Van Guilder M. 1995. Pharmaco-informatics: more precise drug therapy from "multiple model" (MM) adaptive control regimens: evaluation with simulated vancomycin therapy. Medinfo 8(Part 2):1106-1110.
25. Neely MN, Rakhmanina NY. 2011. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin. Pharmacokinet. 50:143-189. http://dx.doi.org/10.2165/11539260-000000000-00000.
26. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. 2011. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann. Pharmacother. 45:757-763. http://dx.doi.org/10.1345/aph.1P634.
27. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. 2010. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int. J. Antimicrob. Agents 35:156-163. http://dx.doi.org/10.1016/j. ijantimicag.2009.10.008.
28. D'Argenio DZ, Schumitzky A, Xiaoning W. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
29. The R development core team. 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
30. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57:5811-5819. http://dx.doi.org/10.1128/AAC.00867-13.
31. Roberts JA, Norris R, Paterson DL, Martin JH. 2012. Therapeutic drug monitoring of antimicrobials. Br. J. Clin. Pharmacol. 73:27-36. http://dx.doi.org/10.1111/j.1365-2125.2011.04080.x.
32. Roberts JA, Hope WW, Lipman J. 2010. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int. J. Antimicrob. Agents 35:419-420. http://dx.doi.org/10.1016/j.ijantimicag.2010.01. 022.
33. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. 2012. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study. Ther. Drug Monit. 34:160-164. http://dx.doi.org/10.1097/FTD.0b013e31824981a6.
34. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. 2002. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 28:936-942. http://dx.doi.org/10.1007/s00134-002- 1313-7.
35. Pea F, Viale P, Cojutti P, Furlanut M. 2012. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe Gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob. Agents Chemother. 56:6343-6348. http://dx.doi.org/10.1128/AAC.01291-12.
36. Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG. 2012. Quantification of seven β-lactam antibiotics and two β-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int. J. Antimicrob. Agents 40:416-422. http://dx.doi.org/10.1016/j.ijantimicag. 2012.06.022.
37. Briscoe SE, McWhinney BC, Lipman J, Roberts JA, Ungerer JPJ. 2012. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 907:178-184. http://dx.doi.org/10.1016/j.jchromb.2012.09.016.
38. Hope WW, Vanguilder M, Donnelly JP, Blijlevens NMA, Brüggemann RJM, Jelliffe RW, Neely MN. 2013. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob. Agents Chemother. 57:1888-1894. http://dx.doi.org/10.1128/AAC.02025-12.